PHARMACEUTICAL COMPOSITION COMPRISING THROMBOLYTIC PEPTIDE-TETRAHYDROISOQUINOLINE CONJUGATE

The present invention provides a pharmaceutical composition comprising a binary conjugate, DC009, which is a conjugate of a thrombolytic peptide (Pro-Ala-Lys) and a tetrahydroisoquinoline compound having two C1-4 alkyl groups via a lysine linking arm, and a pharmaceutical acceptable carrier. The com...

Full description

Saved in:
Bibliographic Details
Main Author CHOU, David Chih-Kuang
Format Patent
LanguageEnglish
French
Published 01.04.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides a pharmaceutical composition comprising a binary conjugate, DC009, which is a conjugate of a thrombolytic peptide (Pro-Ala-Lys) and a tetrahydroisoquinoline compound having two C1-4 alkyl groups via a lysine linking arm, and a pharmaceutical acceptable carrier. The composition has a pH less than 6.5, preferably has a pH about pH 2-5.5 The composition may comprise a pharmaceutical acceptable excipient such as mannitol, sorbitol, sucrose, lactose, or trehalose. La présente invention concerne une composition pharmaceutique comprenant un conjugué binaire, DC009, qui est un conjugué d'un peptide thrombolytique (Pro-Ala-Lys) et un composé de tétrahydroisoquinoléine ayant deux groupes alkyle en C1-4 par l'intermédiaire d'un bras de liaison en lysine, et un support pharmaceutiquement acceptable. La composition a un pH inférieur à 6,5, de préférence a un pH d'environ 2 à 5,5 la composition peut comprendre un excipient pharmaceutiquement acceptable tel que le mannitol, le sorbitol, le saccharose, le lactose ou le tréhalose.
Bibliography:Application Number: WO2020US52514